

ASFOTASE ALFA

BRAND NAME	STRENSIQ
DRUG CLASS	Enzyme
AVAILABILITY	Vial contains 12 mg/0.3 mL, 18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL or 80 mg/0.8 mL of asfotase alfa. Also contains sodium chloride, sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate. ¹ The solution is clear and colourless to slightly yellow. ¹
pH	No information
PREPARATION	Not required. Allow to reach room temperature. ¹
STABILITY	Store at 2 to 8 °C. Do not freeze. Protect from light. ¹ Stable for 3 hours at room temperature. ¹
ADMINISTRATION	
IM injection	Not recommended ¹
SUBCUT injection	Suitable for children and adults. ¹ Inject into the abdomen, upper outer arm or front of the thigh. ^{1,2} If the volume of the dose is more than 1 mL, split the dose equally between 2 or more syringes and inject at separate sites. Rotate the site of injection. ¹ Suitable for self-administration after appropriate patient education. ¹
IV injection	Not recommended ¹
IV infusion	Not recommended ¹
COMPATIBILITY	Do not mix with other medicines
INCOMPATIBILITY	No information
SPECIAL NOTES	Injection site reactions include redness, rash and pruritus. ¹ Hypersensitivity reactions including anaphylaxis have been reported. ¹

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 28/01/2021.
2. Consumer medicine information. Available from www.tga.gov.au. Accessed 28/01/2021.